Four books by Mark A. Smith
A practical foundation, a closer look at rapamycin, a critical conversation about brain health, and a guide to the changing metabolic landscape. Read the questions, the evidence, and the limits.
Book 01 / Healthspan & evidence
Mark A. Smith
A risk-first framework for thinking about healthspan: fitness, nutrition, sleep, useful measurement, and low-risk lifestyle experiments. Learn to distinguish meaningful outcomes from persuasive numbers.
Book 02 / Rapamycin & muscle
Mark A. Smith
An examination of mTOR biology, rapamycin research, and the tension between growth, repair, and aging. Human trials, immune resilience, glucose tolerance, and muscle provide the tests of the theory—not a dosing protocol.
Book 03 / Brain health & prevention
Mark A. Smith
The expanded edition: reporting from public Rapamycin News discussions, refreshed through October 2026 and checked against scientific literature and trial records — including the semaglutide EVOKE trials, blood-pressure prevention evidence, and the arrival of the anti-amyloid antibodies. Evidence is graded by kind, with intervention dossiers, biomarker worksheets, and a watch list rather than a treatment protocol.
Book 04 / GLP-1 & metabolic health
Mark A. Smith
From appetite and cardiovascular outcomes to lean mass and long-term maintenance, a close reading of GLP-1 evidence. Emerging peptides, compounding, and gray-market products are examined with clear attention to safety and regulatory distinctions.
Read with context
These books are works of reporting, education, and scientific interpretation—not medical advice. They do not establish that rapamycin extends human lifespan or that any intervention reliably prevents Alzheimer’s disease. Discuss individual treatment decisions with a qualified clinician; trial results and regulatory status can change.
Green Man updates
New longevity research, fresh perspectives, and book releases—straight to your inbox.